white → yellow2
Not yet reviewed — this article is pending editorial review by Lyrea.
Citation noticeOur citation system is being overhauled
References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.
CRL-40-941
Fladrafinil (developmental code name CRL-40,941) is a wakefulness-promoting agent chemically related to modafinil and adrafinil, of which it is the bis(4-fluoro) phenyl ring-substituted derivative. Apparently first patented in the 1980s, it was never marketed and is instead sold online and used non-medically as a nootropic. In animals it produces antiaggressive effects that adrafinil does not, reportedly with three to four times the potency.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold~50 mg
Light50-100 mg
Moderate100-250 mg
Strong250+ mg
Heavy350+ mg
Duration
Onset30-90 minutes
After Effects1-10 hours
Total6-14 hours
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
Fladrafinil is used non-medically as a wakefulness-promoting agent and purported cognitive enhancer. The available material describes it only in these general terms and does not document the character or course of the subjective experience.
Physical
Pharmacology
Pharmacodynamics
Fladrafinil is a wakefulness-promoting agent related to modafinil. Modafinil and its analogues are known to act as dopamine reuptake inhibitors, and this is thought to be involved in their wakefulness-promoting effects. Fladrafinil has been found to produce antiaggressive effects in animals, which adrafinil does not produce, and is purportedly 3 to 4 times more potent than adrafinil in this action.
Pharmacokinetics
The pharmacokinetics of fladrafinil are being studied.
Metabolitesnone documented yet
Interactions
Interactions not written up yet
An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.
Tolerance
Tolerance not written up yet
Harm Potential
Harm Potential not written up yet
History & Culture
Fladrafinil, developed under the code name CRL-40,941 and also referred to as fluorafinil or bisfluoroadrafinil, appears to have first been patented in the 1980s. It was never brought to market as a pharmaceutical.…
Legality
Legality not written up yet
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass reviewPending
Not yet reviewed — this article is pending editorial review by Lyrea.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes7 human edits · latest
Times are UTCNewest first
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the CRL-40-941 article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.